Page 25 - Pharma Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

in Taiwan May 4, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has launched VYZULTA ® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan. Regulatory approval in Taiwan was obtained in March 2020. VYZULTA has also recently received approval in Qatar. In addition to Taiwan, VYZULTA is commercialized in the United States (since 2017), Canada (2019), Arg...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 ... Erytech Pharma S.A.April 28, 2021 GMT ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details Publication of Q1 2021 results on 4 May 2021 after market close Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red b...

U.S. Patent Office Issues Notice of Allowance for Nicox's Latanoprostene Bunod in Normal Tension Glaucoma April 27, 2021 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as VYZULTA , for the reduction of intraocular pressure in...

and for future value as we continue the development of our clinical assets NCX 470 in glaucoma and NCX 4251 in blepharitis.” Latanoprostene bunod, the pharmaceutical active ingredient in VYZULTA, was invented and patented by Nicox, and is the first product from the company’s proprietary nitric oxide-donating research platform to be approved for commercialization. Under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the “Hatch-Waxman Act”) certain patents for pharmaceutical products in the U.S. may be extended by...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL Erytech Pharma S.A.April 20, 2021 GMT ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the NOPHO-sponsored Phase 2 clinical trial Lyon (France) and Cambridge, MA (U.S.), April 2...